Perrigo receives FDA final approval for generic equivalent to Prandin Perrigo announced that it has received final approval from the FDA for its abbreviated new drug application for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013.
Galmed and Perrigo sign agreement for aramchol API production Galmed (GLMD) has entered into a Manufacturing Services Agreement with Perrigo (PRGO) subsidiary Perrigo API Ltd. for the large-scale production of the active pharmaceutical ingredient of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. The agreement also provides Perrigo with the option to manufacture commercial supplies of the aramchol API in the future.